• Species Reactivity

  Human

• Specificity

  Detects human LRIG1 in ELISAs. In direct ELISAs, less than 5% cross-reactivity with recombinant mouse LRIG1 and recombinant human LRIG3 is observed.

• Source

  Monoclonal Mouse IgG    _2B Clone # 789211

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  HEK293 human embryonic kidney cell line transfected with human LRIG1    
  Ala35-Ser779    
  Accession # Q96JA1

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Flow Cytometry

  2.5 µg/10    ⁶ cells

  See below

• 
  

• Immunohistochemistry

  8-25 µg/mL

  See below

• 
  

• CyTOF-ready

  Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

• 
  

• Immunocytochemistry

  8-25 µg/mL

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Reconstitution

  Sterile PBS to a final concentration of 0.5 mg/mL.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LRIG1

LRIG1 (leucine-rich repeats and Ig-like domains-1; also LIG-1) is an approximately 134-145 kDa glycoprotein that belongs to the LRIG gene family. It is widely expressed and appears on the surface of prostatic epithelium, endothelial cells, vascular and visceral smooth muscle, mammary epithelium, cardiac muscle, keratinocytes and neurons. LRIG1 is believed to negatively regulate the ErbB family of receptors. In particular, and in a ligand-independent manner, LRIG1 complexes with all four ErbBs, promoting their ubiquitination and decreasing their number. Alternatively, LRIG1 is suggested to bind to the ErbBs, preventing their dimerization and signal transduction. Mature human LRIG1 is a 1059 amino acid (aa) type I transmembrane protein. It contains a large 760 amino acid (aa) extracellular domain (ECD) (aa 35-794) plus a 278 aa cytoplasmic region. The ECD contains 17 LRRs (aa 35‑491) and three C2-type Ig-like domains (aa 495-780). These two domain types are each sufficient for EGFR binding. There are two potential alternative splice forms. One contains a 27 aa insertion after Gly874, while another shows a 24 aa insertion after Lys387 coupled to a Gln substitution for aa 644-691. The LRIG1 ECD undergoes proteolysis, generating 100-110 and 55-60 kDa soluble fragments. Over aa 35‑779, human LRIG1 shares 90% aa sequence identity with mouse LRIG1.

• Long Name:

  Leucine-rich Repeats and Immunoglobulin-like Domains 1

• Entrez Gene IDs:

  26018 (Human); 16206 (Mouse); 312574 (Rat)

• Alternate Names:

  D6Bwg0781e; Img; LIG1; LIG-1; LRIG1